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Abstract - - Posttranscriptional gene regulation 
(PTR) is a fundamental biological process that 
integrates with the master transcriptional control of 
gene expression, in ways that only in the last decade 
have been increasingly understood [1, 2].  While 
epigenetic and transcriptional events shape cell 
response qualitatively, deciding the pattern of gene 
expression to ‘switch on or off’ in response to 
endogenous or environmental triggers, the key task of 
PTR is to act as a ‘rheostat’ and rapidly adapt the 
cellular response by providing the appropriate 
amplitude and timing to the protein expression patterns 
[3, 4]. The pivotal role of this mechanism comes to the 
forefront in inflammatory and immune response, where 
the changes in amplitude and duration in the expression 
of dangerous and protective genes are in delicate 
balance, and are critical in determining either the 
successful resolution of the immune response or its 
chronic overexpression [5].  This brief review introduces 
members of the main classes of molecules mediating the 
cytoplasmic arm of gene regulation, namely RNA-
binding proteins and micro-RNA (miRNA), and 
summarizes experimental data that underscore the role 
of these molecules in the pathophysiology of chronic 
inflammation, as well as their promising value as 
mechanisms conveying the anti-inflammatory effect of 
synthetic glucocorticoids. 
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I.  INTRODUCTION 
 
 In the last decade, seminal studies have identified 
RNA-binding proteins (RBP) and microRNA (miRNA) as 
key mediators of PTR [6-8].  Both classes of molecules are 
regulated by the same signaling pathways – chiefly MAP 
kinases - that modulate transcriptional regulation, 
underscoring the highly integrative nature of the nuclear 
and cytoplasmic gene regulatory events[9, 10]. They are 
among the most abundant and well-conserved eukariotic 
genes and share the property to coordinately regulate 
multiple genes through binding to conserved nucleic acid 
sequences. Often co-localized in cytoplasmic foci of 
mRNA metabolism (P bodies and stress granules),  they can 
regulate each other’s effects by competing for binding or 
complementing the binding of one another [11, 12].  As 
studies are increasingly revealing the complex interactions 
between these determinants of posttranscriptional gene 
regulation and their gene targets, the understanding of their 
potential involvement in the pathophysiology of many 
human chronic inflammatory diseases is a key task for the 
generation of novel therapeutic interventions. 
 
1. Molecular Mediators of Posttranscriptional Gene 
Regulation in Inflammation: RNA-binding proteins and 
micro-RNAs. 
 
Since their generation in the nucleus, mRNA molecules 
are kept as components of ribonucleoprotein (RNP) 
complexes, in association with a host of RNA-binding 
proteins (RBPs) that dynamically interact with the 
mRNAs and modulate their fate: from their correct 
splicing and nucleocytoplasmic transfer, to their turnover 
and translation rates [13]. Several conserved regions 
within the mRNA sequences, where RBPs associate with 
specific RNA Recognition Motifs (RRMs), have been 
identified and recently defined as USER (Untranslated 
Sequence Elements for Regulations), as they are 
preferentially –though not exclusively - located in the 
mRNA untranslated regions (UTR), particularly in the 
3’UTR [1, 2, 14].  Among these, the Adenylate-Uridylate-
Rich Elements (ARE) are the most conserved and well-
characterized regulatory elements mediating changes in 
mRNA turnover and translation in immune and 
inflammatory genes [15]. ARE-mediated gene regulation 
has been described for inflammatory genes such as TNF-
, IL2, IL3, IL-6, GM-CSF,COX-2, INOS, IL4, and IL13 
and many more including numerous chemokines, 
although other USER have been found to be important, 
especially for T cell-derived genes [14].  Genome-wide 
studies examining the transcript pools selectively 
associated with distinct RBPs have established that 
functionally related mRNAs that share a USER, such as 
the ARE, can be coordinately regulated by one or more 
cognate RBPs [1, 16].  In order to regulate their targets’ 
mRNA stability and/or translation,  multiple ARE-binding 
proteins bind dynamically to the mRNA targets following 
the cues of signaling pathways triggered by 
proinflammatory stimuli [13] and acting either in a 
cooperative or exclusive fashion.    
Exemplary of these complementary actions are the two 
ARE-binding proteins HuR and tristetraprolin (TTP). They 
both regulate mRNA transcripts binding to a group of 
heterogeneous and distinct, but partially overlapping ARE 
highly conserved in the 3’UTR of inflammatory and 
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immune genes’ mRNAs, such as TNF, IL-6, GM-CSF, 
COX-2, INOS, CCL2 and more [17-19].   
While the ubiquitous RBP HuR is functionally 
characterized mainly as a positive regulator of mRNA 
stability and translation, TTP limits the inflammatory 
response by accelerating the mRNA decay of its targets 
[13].   In particular, cell activation induces HuR 
nucleocytoplasmic shuttling [20-24], an event reflecting 
its functional activation, which leads to increased protein 
output for several inflammatory genes, by making their 
mRNA more stable and/or by increasing their translation 
rates [22, 25-31] acting through multiple, often 
independent mechanisms yet to be fully characterized 
[32].   
An important functional counterpart of  HuR-
mediated increase in inflammatory gene expression is TTP.  
Tristetraprolin is a member of a small family of CCCH 
zinc finger proteins that include TTP, Butyrate-response 
factor (BRF)-1 and BRF-2 [33].  Tristetraprolin promotes 
mRNA decay through binding of its zinc finger RRM 
domain to an ARE consisting in adjacent UUAU/UUAU 
half-sites [34-36].   Stress and inflammatory stimuli 
induce TTP as an immediate early response gene in 
numerous cell types, including T cells, macrophages, 
epithelial cells and fibroblasts, where it predominantly 
resides in the cytoplasm [37].  TTP is a potent 
endogenous negative regulator of TNF-induced 
inflammation through a negative feedback loop on its 
activity: in fact, TNF-α induces TTP synthesis, which in 
turn leads to rapid destabilization and decay of TNF-α 
mRNA [38].  Besides TNF-, TTP also increases the 
mRNA decay of many targets regulated in opposite 
fashion by HuR [17, 39-42].  Additional TTP-regulated 
transcripts have been identified in a genome-wide study 
of mouse embryonic fibroblasts (MEFs) isolated from 
TTP-knockout (TTP-/) mice [18], and in mouse 
macrophages in which TTP expression was silenced [43].  
The importance of TTP in limiting the inflammatory 
response has been clearly demonstrated also in vivo using 
TTP-deficient mice, which develop severe inflammatory 
arthritis, autoimmune dysfunction and myeloid 
hyperplasia through the deregulated expression of TNF-α 
and GM-CSF [44]. 
Micro-RNAs (miRNA) are small (approximately 
20-25 nucleotides long), endogenous RNAs encoded by 
one of the largest and most conserved family of genes in 
eukariotes, which regulate gene expression at a post-
transcriptional level mainly with a repressive outcome 
[45], though miRNA-mediated increase in gene 
translation has also been reported in cell-cycle processes 
[46]. It is estimated that up to one third of the human 
genome may be subject to regulation by miRNAs [47]. 
Such large control is exerted through the coordinate effect 
of a single miRNA on multiple transcripts, which are 
often functionally related, which harbor the seed regions 
and display other complex structural features dictating 
functional miRNA:mRNA interaction.  Furthermore, a 
single transcript is targeted by multiple miRNAs, such 
that a highly combinatorial miRNA profile is what 
ultimately fine-tunes the protein levels of a high number 
of targets. MiRNAs act through multiple mecanisms, 
mediating either mRNA degradation or translation 
repression of their targets, though they also convey 
indirect effects on epigenetic and transcriptional 
regulatory factors [48, 49]. Research in the past decade 
has revealed their key role in fundamental biological 
processes such as cell development, proliferation and 
apoptosis [50], and consequently the immune system and 
the inflammatory response has resulted to be greatly 
influenced by miRNA functions[51-56].  Alteration of 
miRNA expression/function has been increasingly 
revealed in disease pathophysiology, including 
inflammatory and allergic diseases [55, 57-60].  As such, 
modulation of miRNA function, either with miRNA 
mimics or antagonists (denominated antagomiRs [53]), 
has increasingly pursued as a strategy to convey 
therapeutic effect [61, 62].  Importantly, recent studies 
show that miRNA and RBP can interact through common 
or overlapping site(s) of their target mRNAs, and their 
interaction can bring either cooperative or antagonistic 
outcomes [11, 63, 64].  Thus, it is critical to understand 
not only how these regulatory factors are modulated by 
immune activation, but also how their relative 
contribution is influenced by their relation with other 
components of the ribonucleoprotein complex. 
 
2. 2. Does deregulation of PTR impair the resolution of the 
inflammatory response?   
3.  
4. Despite great advancements in the understanding of the 
basic mechanisms conveying PTR in inflammation [3], 
evidence of the pathophysiological impact of PTR in 
human allergic, infectious and inflammatory diseases is 
lagging behind - although data pointing at its importance 
are accumulating.  To begin with, pro-inflammatory 
signaling pathways known to be activated in allergic and 
inflammatory diseases, such as the stress-activated MAP 
kinases, are now known to be key regulators of PTR and in 
particular, of the activation and function of RBPs [13, 65].  
For example, in asthmatic patients, the ERK1/2 and p38 
pathways, which regulate key cell secretory function and 
proliferation, are strongly upregulated in airway epithelium 
and BAL macrophages, and their increase correlates with 
asthma severity  and response to GC therapy [66, 67]. 
These two pathways are established, potent regulators of 
TTP and HuR, by inhibiting the first and activating the 
latter [68, 69]. These evidences strongly suggest that 
alteration of the components within the ribonucleoprotein 
complex that regulates mRNA decay and translation may 
play a pathogenetic role in chronic inflammatory disorders 
such as asthma or rheumatoid arthritis.  It can be 
hypothesized that inflammatory and/or microbial triggers 
may produce an aberrant shift of the PTR balance towards 
increased mRNA stability and translation of the gene pool 
coordinately regulated through these mechanisms, 
determining an increase in the amplitude and prolongation 
in time of the gene expression profile defined 
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transcriptionally. 
 
3. Posttranscriptional mechanisms in glucocorticoid’s 
anti-inflammatory action: a novel focus for anti-
inflammatory strategies. 
 
It is firmly established that the mechanism of the 
antiinflammatory action of synthetic glucocorticoids (GC) 
critically relies on their ability to influence gene 
expression through transcriptional regulation [70].  More 
recent data, however, indicate that control of 
posttranscriptional pathways could constitute  a critical 
component of an efficient anti-inflammatory action [71, 
72]. Understanding the pathophysiological role of PTR 
mediators, such as RBPs and miRNAs, and to what extent 
they may convey an anti-inflammatory function may lead 
to novel anti-inflammatory strategies.  
GC have been known to accelerate the mRNA 
decay of a growing number of cytokines, chemokines and 
other pro-inflammatory molecules, but the molecular 
mechanisms by which GCs act on post-transcriptional 
events are still very poorly understood [71]. 
Glucocorticoids can impact PTR in different ways.  An 
important indirect effect occurs through the induction by 
GC of MAP Kinase Phosphatase-1 (MKP-1), a 
phosphatase that inhibits p38 MAP kinase activity, which 
induces stabilization of many mRNA species relevant to 
inflammation (cytokines, chemokines, cyclooxygenase-2) 
[73].  Mouse lacking MKP-1 demonstrate a diminished 
response to GC [74]. 
Studies conducted by our laboratory and others 
indicate that GC induce TTP [75] [19].  In our study, 
genome-wide analysis using mouse embryonic fibroblasts 
(MEF) from TTP-/- and wild type (WT) littermates revealed 
that GC-mediated changes in gene expression were 
strikingly dependent from TTP, with a loss of GC 
sensitivity for more than 80% of genes that were GC-
responsive in WT MEFs [19]. We confirmed the loss of 
GC-mediated action for several TTP targets in cultured 
human primary bronchial epithelial cells, using siRNA-
mediated TTP ablation.  Conversely, in a mouse model of 
LPS-induced peridontal inflammation, TTP 
overexpression displayed an antiinflammatory effect 
through accelerated turnover of TNF- mRNA [76]. 
These studies indicate that the impact of posttranscriptional 
regulation in the mechanism of anti-inflammatory action of 
GCs is larger than ever appreciated and it involves 
molecules, like TTP, that directly modulate mRNA stability. 
However, As TTP is regulated by TNF and other 
inflammatory stimuli both at the level of expression and 
functional state by MAP kinases, which functionally 
inactivate TTP [69, 77-79], in order to exploit TTP-
mediated action GC would need to increase TTP levels and 
regulate its functional state, by controlling the 
inflammatory signaling that suppress it or by supporting the 
cellular pathways that counteract the inflammation.  
Therefore, we are currently testing the hypothesis that if 
TTP would be increased in level and functionally active 
under GC control, its physiologic role in the termination of 
the inflammatory response would contribute significantly to 
the GC-mediated shutdown of inflammatory cytokines, by 
allowing increased mRNA decay for the many ARE-
bearing inflammatory transcripts under TTP control. More 
recently, we and others [80, 81] have characterized a 
novel cytoplasmic role of the glucocorticoid receptor 
(GR) in posttranscriptional gene control, describing that 
in airway epithelial cells, GR may also function as an 
RNA-binding protein. Proteins functionally characterized 
as transcription factors, such as the GR, and RBPs have 
several features in common, such as stimulus- or ligand-
induced nucleocytoplasmic shuttling function and the 
ability to coordinately regulate multiple genes through 
binding to conserved nucleic acid sequences. Some 
regulatory factors can bind to both DNA and RNA, thus 
influencing both transcription and mRNA fate.  For 
instance, the zinc finger protein NF-90 can regulate 
transcription of IL-2, but can also bind to and stabilize the 
IL-2 mRNA [82].  Initial studies done in rat smooth 
muscle cells reported that the GR interact with the mRNA 
of the chemokine CCL2, and that the presence of the GR 
in the RNP complex was necessary for its degradation to 
occur [80].  This work identified a novel role of GR in 
mRNA turnover, and raised questions about the scope and 
mechanisms underlying this process. Given the 
importance of GC action in modulating inflammatory 
gene expression in human airway epithelium, and given 
the relevance of other RBPs, such as TTP, in GC action 
[19],  we sought to investigate whether the GR would act 
as an RBP in human airway epithelial cells, reasoning 
that, as  RBPs can coordinately regulate subsets of 
functionally related transcripts that share a common 
recognition motif, such action may regulate not only few 
targets but a substantial subset of genes[1].  We first 
identified the association of GR with the chemokines’ 
CCL2 and CCL7 mRNAs by immunoprecipitation of 
ribonucleoprotein complex (RNP-IP) and biotin pull-
down in the human airway epithelial cell line BEAS-2B.  
In the case of CCL2, the binding site was mapped to the 
5’UTR of the transcript.  Furthermore, we aimed at 
identifying the full complement of transcripts that could 
bind to GR using a ribonomic approach, and 
computationally searched for a common GR recognition 
motif within the identified GR target transcripts.  We 
demonstrate that the GR in human lung epithelial cells is 
capable of associating with almost 500 transcripts, and we 
validated such association for a subset of them. Finally, 
we identified by computational analysis a novel, GC-rich 
motif, for which we confirmed GR association, present in 
the 5’ UTRs of 7889 predicted mRNA targets, or in the 
entire sequences of 25,672 predicted mRNA targets (21% 
of the UniGene transcript pool) [81].   
Overall, these data indicate that the GR can 
mediate GC action beyond its nuclear functions in 
transcriptional control, and that it may directly participate, 
via association with mRNA, in GC-mediated control of 
cytoplasmic mechanisms of gene expression.  Though 
these data indicate an intriguing novel regulatory 
mechanism for the GR, much remains to be tested to 
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understand its relevance in the global anti-inflammatory 
action of GC: for example, whether the functional role of 
the RNA motif is indeed to convey acceleration of mRNA 
decay, as documented for CCL2 and CCL7, and whether 
other GR motifs can be found in genes expressed upon 
inflammatory cell activation.  To this end, multiple motifs 
have been documented for the RBP TIAR, which binds to 
U-rich motifs within the 3’UTR of its targets with high 
affinity when conveying translational repression, while its 
low-affinity binding to a C-rich element decreases upon 
cellular stress [83].  Likewise, it can be postulated that 
GC treatment, as well as a host of intra- and extracellular 
triggers, could modulate the GR binding to the RNA 
motifs in many ways.  For example, this process could be 
modified by stimulus-induced changes in the RBP and 
microRNA potentially associated with GR in the RNP 
complex, and/or by action upon the association of GR-
bound RNA with cytoplasmic foci of regulated mRNA 
decay and translation, such as P bodies and stress 
granules, where these functions are critically regulated 
during inflammation. On the structural level, much 
remains to be discovered on the cytoplasmic GR:mRNA 
association, starting from the identification of the GR 
domain interfacing with the GC-rich motif and the 
stoichiometry of this binding: what we know so far is that 
the GR lacks a conserved RNA-binding domain (RBD), 
present in other transcription factors that also bind to 
mRNA, like NF-90 and in nucleolin  [84, 85].  In addition 
to a specific RBD, GR could also associate to other RBP 
components that bind directly to RNA.     
Research on the role of miRNA in GC anti-
inflammatory action is still in its infancy. The effect of 
GC in a mouse model of LPS-induced inflammation was 
minimal on global miRNA profiling in the lungs [86], as 
it was in a study of miRNA profiling in bronchial biopsies 
of mild asthmatics before and after therapy with inhaled 
glucocorticoids [87].  Given that miRNA expression is 
cell-specific, discrete changes may have been masked by 
the evaluation of tissue samples rather than purified cells. 
In line with this consideration, in fact, recent data indicate 
that GC potently inhibits in a macrophage cell line the 
expression of miR101, a suppressor of MKP-1 [88] and 
strongly repress miRNA expression during 




II.  CONCLUSION 
 
In conclusion, growing data indicate the existence of 
relevant, yet understudied molecular mechanisms 
involved in the physiologic control of the inflammatory 
response that could provide a different paradigm of anti-
inflammatory approach, shifting from the control of 
master transcriptional mechanisms to that of 
posttranscriptional regulatory events. RNA-binding 
proteins and miRNA are increasingly seen as critical and 
targetable effector molecules of inflammation. 
Considering that both molecular species coordinatley 
regulate functionally related pools of transcripts through 
common regulatory elements, intervening at the structural 
and functional interface between RBPs, miRNAs and 
their targets may convey a relatively specific anti-
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